Should advanced lipoprotein testing be used in clinical practice?

Nature Clinical Practice Cardiovascular Medicine

Volumn 3, Issue 12, 2006, Pages 640-641

  Stein, James H ^a   McBride, Patrick E ^a,b  

^a Preventive Cardiology Program   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B100; CHYLOMICRON; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROGENESIS; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CORONARY ARTERY RECANALIZATION; CORRELATION ANALYSIS; DISEASE MARKER; DYSLIPIDEMIA; DYSLIPOPROTEINEMIA; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; METABOLIC SYNDROME X; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; ROC CURVE; SUDDEN DEATH; TRIACYLGLYCEROL BLOOD LEVEL;

APOLIPOPROTEIN B-100; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; DYSLIPIDEMIAS; HUMANS; LIPOPROTEINS; PARTICLE SIZE; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 33751359629     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio0719     Document Type: Review

References (10)

1. Grundy SM et al. (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110: 227-239
2. Superko HR (1996) Beyond LDL cholesterol reduction. Circulation 94: 2351-2354
3. Fredrickson DS et al. (1967) Fat transport in lipoproteins - an integrated approach to mechanisms and disorders. N Engl J Med 276: 148-156
4. Cromwell WC and Otvos JD (2004) Low-density lipoprotein particle number and risk for cardiovascular disease. Curr Atheroscler Rep 6:381-387
5. Kathiresan S et al. (2000) Increased small low-density lipoprotein particle number: A prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 113:20-29
6. Sniderman AD et al. (2003) Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol 91: 1173-1177
7. Blake GJ et al. (2002) Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 106: 1930-1937
8. Olsson A at al. (2006) Apolipoprotein B/A1 ratio is a better discriminator of risk of coronary heart disease than is LDL/HDL cholesterol ratio in the IDEAL study [abstract #Tu-W20:4]. Atheroscler 7 (Suppl): 161
9. Sattar N et al. (2004) Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study. Circulation 110: 2687-2693
10. Barter PJ et al. (2006) Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy; report of the thirty-person/ ten-country panel. J Intern Med 259: 247-258